Background/aims: Network structure and individuals' level of exposure to a pathogen can impact results from efficacy evaluation studies of interventions against infectious diseases. Heterogeneity in infection risk can cause randomized groups to increasingly differ as a trial progresses and as more high-risk individuals become infected (described in prior work as the ''frailty'' phenomenon). Here, we show the impact this phenomenon can have on an individually randomized trial of a leaky vaccine in which all participants are exchangeable a priori. Methods: We model a vaccine trial by generating a network of individuals grouped into communities, which are connected to a larger main population. We then simulate an epidemic, deterministically and with time-varying transmission rates in the main population and stochastically in the communities. The disease natural history follows a susceptible-exposed-infectious-recovered model. Simulation results are used to estimate vaccine efficacy ( c VE) with a Cox proportional hazards model. Results: We find downward bias in c VE associated with low connectivity between communities in the study population and high force of infection, even when all participants in the trial are exchangeable at the time of randomization. This phenomenon arises because the stochastic dynamics in such a setting randomly lead to community-level variation in the force of infection. Stratifying a Cox model by community alleviates this bias with no loss of power. Conclusion: Understanding and accounting for the impact of heterogeneous hazard rates can allow for more accurate estimates of c VE in epidemic settings.
Network structure and individuals' degree of exposure to a pathogen can affect the efficacy analysis of interventions against infectious diseases. The ''frailty'' phenomenon, whereby heterogeneity in infection risk can cause randomized groups to increasingly differ as a trial progresses and more high-risk individuals become infected, has been well documented. [1] [2] [3] Using a timeweighted hazard-ratio analysis, such as a Cox model, when heterogeneity in infection risk exists can induce bias in the vaccine efficacy (VE) estimate ( c VE) relative to the true direct VE. 4 The heterogeneity often occurs when a group of individuals has a higher risk of exposure compared to others a priori. 3, 5 Through simulation, we characterize the magnitude and direction of the bias of c VE induced by heterogeneity of hazard rates in an individually randomized controlled trial of a leaky vaccine in which all participants are exchangeable at the beginning of the trial. We show that heterogeneous risk of infection arises due to the stochastic nature of epidemic dynamics in small populations, which leads individuals in some communities to experience higher infection risk than others. We then show that stratifying the analysis by community removes this bias without loss of power.
Methods
We model a vaccine trial by first generating a network of individuals grouped into communities, which are connected to a larger main population. Community size is uniformly distributed on a given range, with the mean community size and range as model inputs (Table 1) . The average number of connections individuals have with individuals in their own community and the average number of connections individuals have to those in other communities are each additional inputs of the model. Therefore, while individuals in the communities are not identical in terms of their exact number of connections, they are exchangeable in expected degree.
We then simulate a deterministic epidemic in the main population with a time-varying transmission rate and stochastic epidemics in each of the communities. The disease natural history follows a susceptibleexposed-infectious-recovered model. A connection between two people represents a daily contact between them, meaning all susceptible individuals have a daily probability of infection from each of their infectious neighbors of 1 2 e 2b , where b is the force of infection for that contact. Additionally, each individual experiences a daily external hazard of infection from the main population, which varies with the prevalence of infection in the main population (Table 1) .
About 7.5% of the population in the communities is enrolled into the trial, and individuals are randomized to either the vaccine or control groups. The vaccine is leaky, meaning that it reduces the probability of infection upon each exposure to an infectious individual; 9, 10 for those vaccinated, the daily probability of infection from their infectious contacts is 1 2 e
2b(12VE)
, where VE represents the direct leaky multiplicative VE input into the model. We estimate c VE with a Cox proportional hazards model for time to symptom onset, with trial status (i.e. vaccine or control) as the explanatory variable. Individuals who are never infected are censored at the end of the study period. We estimate c VE both unstratified and stratified by community. Power is estimated by the proportion of simulations in which the p-value associated with the estimated c VE is less than 0.05 and c VE.0. We also estimate c VE from simulations of a trial of a vaccine with all-or-nothing effects, meaning it protects a certain percentage of people completely and others not at all, as well as from simulations varying different parameters, such as VE, the size of the communities, and the percent of each community enrolled into the trial. Additionally, we estimate c VE within subsets of the trial population, as subset analyses are often done, for example, within age groups or by sex.
Results
Using an unstratified Cox proportional hazards model to estimate c VE returns a downward bias in c VE relative to the input direct VE. As shown in Figure 1 (a), when input VE is set to 0.6, c VE from the unstratified analysis is less than 0.6. The bias increases with increases in R 0 and decreases as communities become more connected to each other. A Cox model stratified by community alleviates the bias without reducing power ( Figure 1(b) ). This bias does not occur when the input VE is set to 1 or 0 (see Figures S1 and S2 ). As expected, this bias also does not occur in a risk-based analysis of a vaccine with all-or-nothing effects (see Figure S3) ; however, a rate-based analysis of a vaccine with all-ornothing effects returns an upward bias in c VE relative to the input direct VE (see Figure S4 ). [9] [10] [11] We find that heterogeneity in hazard rates in an individually randomized vaccine trial with a leaky vaccine leads to a downward bias of c VE even when all individuals are exchangeable at the start of the trial. Although the simulated network structure does not assign anyone to be high risk a priori (i.e. everyone has the same initial risk of infection), heterogeneity in exposure still arises. Given the stochastic nature of epidemic dynamics, which includes introductions into the trial population from the larger main population, certain communities have larger outbreaks while others escape infection entirely. Individuals in a community with a large outbreak experience more exposure to infection than those in which there is not a large outbreak. This heterogeneity in hazard is well known to create a downward bias in c VE 2,9,10 because the individuals at greater risk of infection (here, the individuals in communities with larger epidemics) are depleted more rapidly from the control group than individuals at less risk of infection, making the average hazard in the control group more similar to that in the vaccine group over the course of the trial. When R 0 is higher, individuals in communities with large outbreaks are exposed at an even higher rate than at lower levels of R 0 , further exacerbating these effects. As communities become more connected, the heterogeneity in exposure between communities decreases because large outbreaks spill over into neighboring communities, alleviating some of the bias.
It is possible to show the source of the bias from the unstratified analysis in a causal directed acyclic graph (Figure 2 ). Let A be an indicator for vaccination status at baseline, Y t = 1 an indicator for infection at an early time point, and Y t = 2 be an indicator for infection at a second time point. Hazard ratio estimation at time = 2 conditions on those who were not infected at time = 1 (Y t = 1 = 0), and the Cox model uses a weighted average of the time-specific hazard ratios. 4 Conditioning on Y t = 1 opens a backdoor path from A to Y t = 2 , biasing the estimates of the effect of A on Y t = 2 .
12 As shown in Figure 1(a) , the bias induced by heterogeneity in hazard rates across communities can be reduced by adjusting for community in a stratified Cox model analysis. This is because the backdoor path is blocked by conditioning on community.
We might expect the unstratified estimate to be biased due to a violation of the Cox model's proportional hazards assumption. To evaluate this hypothesis, we conducted a weighted residuals test for violation of proportional hazards of the unstratified analysis, 13 and then assessed the correlation between the resulting p-value and the difference between the stratified and Causal directed acyclic graph of bias in unstratified analysis. Conditioning on those who were not infected at time = 1 in the analysis at time = 2 opens a backdoor path between A (vaccination status) and Y t = 2 (outcome at time = 2), inducing bias. 12 The dashed arrows indicate uncertainty regarding the relationship between A and Y, or the vaccine efficacy, which the trial aims to estimate. Note only two times shown for simplicity.
unstratified c VE. This test did not provide a clear indication of bias in the unstratified estimate (correlation = 0.02, p-value = 0.80) and thus should not be used to determine if stratification is necessary to obtain an unbiased estimate. In settings with fairly disconnected communities where there is potential for heterogeneity in hazard rates, we recommend conducting a stratified analysis. Although an individual frailty model could also alleviate the downward bias, stratification alleviates the bias without reducing power discernibly for the baseline assumptions considered here. However, when the sample size is very small, for example, in the case of a subset analysis, stratifying to reduce bias leads to a loss of power (see Figure S5) .
Defining ''community'' for the purpose of stratification may present a challenge. While incorporating network structure into the design and analysis of trials is more often discussed in the context of cluster randomized trials, network surveys could also be used to identify the best unit for stratification in individually randomized trials.
14 However, as shown in Figure 1 , the downward bias of the unstratified analysis is noticeable only when the connections outside an individual's community are less than 20%. In such a disconnected network, the communities will likely be distinct enough to identify, whereas in settings in which defining a community becomes more challenging, stratification will likely be unnecessary.
Further analysis indicates that the bias is not dependent on the size of the communities or the number of people from each community enrolled into the trial. An analysis with larger communities and a 10-fold increase in the number of people from each community enrolled into the trial also results in a downward bias in VE estimate, which is alleviated by stratification (see Figure  S6 ).
Conclusion
It is well known that heterogeneity leads to a bias in c VE.
3,5 However, it has previously only been discussed in the context of risk factor heterogeneity, either measured or unmeasured. Here, we show that this bias can arise, and be alleviated, even when a priori heterogeneity does not exist.
While these findings are specific to settings with fairly disconnected communities, understanding the potential sources of bias in analysis of vaccine trial results is essential for ensuring accurate estimates of c VE, which are important for the design of both vaccine trials and vaccine programs. Two vaccines that are equally efficacious may appear to have different c VE if tested in different settings and analyzed without stratification, resulting in false conclusions about their relative efficacy. Furthermore, because c VE is required for calculating the vaccine coverage needed in order to achieve herd immunity in a population, an underestimate could lead to unnecessarily expensive vaccination campaigns.
Downward bias in the efficacy estimate for a leaky vaccine can occur in a population with a mixing structure other than complete random mixing, even when all trial participants are exchangeable a priori. Stratification by community, in a setting where mixing within communities is random, completely solves the problem with no loss of power. Stratified Cox models have previously been used in the analysis of VE studies, such as the RTS,S/AS01 Malaria Vaccine individually randomized controlled trial, which stratified by study site. 15 However, such stratification is not a universal practice and was not used in recent analyses of dengue or cholera vaccine trials. 16, 17 Stratification should be considered for future vaccine trials conducted in a large number of relatively disconnected centers, such as the planned Zika vaccine trials.
